Your trusted source for investing success

Tag: clinical trial

FREE Report - How Will Trump Affect Your Gold Investments? 

Trump’s policies are affecting gold. You should know what’s going on. Click here to get our FREE report.

Click here to get your free report!

Discover what the experts see coming in the Age of Trump with our INN Insider's Report free of charge! Includes expert insights into Trump and his effect on mining and gold.

 
Valens issues 322,221 shares from warrant exercise

Valens issues 322,221 shares from warrant exercise

Valens GroWorks Corp. (CSE:VGW) (the “Company” or “Valens”) is pleased to announce the exercise of 322,221 warrants at a price of $0.75 per share, resulting in the issue of 322,221 common shares of the Company. This provides $41,666 cash added to the Company’s treasury, and a $200,000 reduction in payables.

What Is Genomics?

What Is Genomics?

Genomics, the study of genetic information within all living beings provides an insight into a patient’s genetics which opens the possibility to provide a more personalized medicine system.

SeeThruEquity Issues Update on DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI)

SeeThruEquity Issues Update on DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI)

SeeThruEquity, a leading New York City based independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued an update note on DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI).

The note is available here: DMPI October 2017 Update.

DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI)) is a clinical-stage biotechnology firm

Valens Groworks Signs Craftgrow Deal With Canopy Growth

Valens Groworks Signs Craftgrow Deal With Canopy Growth

Valens GroWorks Corp. (CSE:VGW) (“Valens GroWorks”, or the “Company”) is pleased to announce that its wholly owned subsidiary Valens Agritech Ltd. (“Valens”), a Health Canada Licensed Dealer, has signed a supply and sales agreement with Canopy Growth Corporation (TSX: WEED) (“Canopy Growth”) for the distribution, marketing and sale of the

Valens GroWorks Announces Partnership with BC Universities

Valens GroWorks Announces Partnership with BC Universities

Valens GroWorks Corp (CSE:VGW) (the “Company”) is pleased to announce a research partnership with UBC Okanagan and Thompson Rivers University. Dubbed the Cannabis Bio-products Toolbox, this collaborative research project will explore the vast range of bioproducts that can be made from the plant – these include pharmaceuticals, nutritional products, and

Valens Groworks Closes Final Tranche Of Offering

Valens Groworks Closes Final Tranche Of Offering

Valens GroWorks (CSE:VGW)(CSE:VGW.CN) (the “Company” or “Valens“), a vertically integrated provider of cannabis products, is pleased to announce the closing of an additional 85,000 units (the “Units”) for proceeds of $85,000, the final tranche of its non-brokered $1.00 per Unit private placement (the “Offering”) first announced on July 26, 2017. The Offering

Moleculin Signs Agreement with First Hospital for Annamycin Trials

Moleculin Biotech (NASDAQ:MBRX) has announced that it has entered into an agreement to conduct its clinical trial to study Annamycin for the treatment of acute myeloid leukemia.

As quoted in the press release:
“Now that our IND (investigational new drug) application is approved, the race is on to open treatment centers and

Pieris Pharmaceuticals Announces Dosing of First Patient in Phase I Trial for Fully Proprietary Lead IO Program, PRS-343

Pieris Pharmaceuticals (NASDAQ:PIRS) has announced that the first patient has been does in its Phase 1 clinical trial of PRS-343, its lead proprietary immuno-oncology drug candidate.

As quoted in the press release:
PRS-343 is a first-in-class bispecific antibody-Anticalin fusion protein and functions as a tumor-targeted immune costimulatory 4-1BB agonist. The trial, a

Enter Your Log In Credentials
This setting should only be used on your home or work computer.

×

Privacy & Legal Policy

Privacy Policy

×
Investing News Network

Send this to a friend

Hi,
I thought you might find this interesting:
Valens issues 322,221 shares from warrant exercise

URL: https://investingnews.com/daily/resource-investing/agriculture-investing/cannabis-investing/valens-issues-322221-shares-warrant-exercise/